At the Inaugural Columbia Precision Medicine Initiative (CPMI) conference: Advances in Precision Medicine: Genetics, we heard about cutting-edge genetics research from international leaders in the field whose research advances the basic science of genetics and impacts the application of genetics to the understanding and treatment of human genetic disease.
Accomplishing the objectives of CPMI requires advancing basic science, and the application of the resulting knowledge to the identification of genetic causes of human diseases, the understanding of disease mechanisms, and ultimately to the treatment of a wide range of human diseases ranging from cancer to neurological diseases. To this end, CPMI is a truly University-wide effort. The bedrock of the initiative is strong basic and translational biomedical science practiced in the Medical School, the new Zuckerman Mind Brain and Behavior Institute, and the Morningside campus. Success of the Initiative will also require many other academic disciplines at Columbia ranging from humanities, to engineering, to law and business.
With breathtaking advances in DNA sequencing, computer science, and clinical medicine, it is virtually certain that the number of diseases diagnosed and treated on the basis of genome sequence information will increase dramatically during the next decade. In addition, as we learn more about the relationship between genetic mutations, human biology, and disease, the genome sequence will play a central role in the practice of medicine. I believe the technology is here and essential groundwork has been established. Columbia University is ideally positioned to bring the full force of an extraordinarily diverse and talented faculty to bear on the advancement of precision medicine.
Columbia University is a world leader in medicine, science, and technology, from fundamental discoveries to the clinic. The Columbia Precision Medicine Initiative (CPMI) utilizes the vast intellectual resources of Columbia faculty to drive this revolution in health care.
Please join us for our second annual conference: Advances in Precision Medicine: Cancer Genomics. It will be held on Monday April 9th, 2018, on the Columbia University Medical Campus. We will be hosting 10 top international speakers, together bringing a broad focus spanning from research insights to clinical applications of cancer genomics.
Arul M. Chinnaiyan, University of Michigan
Luis Diaz, Memorial Sloan Kettering Cancer Center
Levi Garraway, Eli Lilly and Company
Arnold Levine, Institute for Advanced Studies
William C. Hahn, Broad Institute; Dana-Farber Cancer Institute
Serena Nik-Zainal, University of Cambridge
Raul Rabadan, Columbia University
Nitzan Rosenfeld, University of Cambridge
Charles Sawyers, Memorial Sloan Kettering Cancer Center
David Tuveson, Cold Spring Harbor Laboratory
Catherine Wu, Broad Institute; Dana-Farber Cancer Institute
Please register here.
Last year, at the Inaugural CPMI conference: Advances in Precision Medicine: Genetics, we heard about cutting-edge genetics research from international leaders in the field whose research advances the basic science of genetics and impacts the application of genetics to the understanding and treatment of human genetic disease.